Srinath (Sri) Thirumalairajan, Ph.D. Joins the Editorial Advisory Board of ADC Review | Journal of Antibody-drug Conjugates
ADC Review | Journal of Antibody-drug Conjugates, a peer-reviewed journal published by Sunvalley Communication, LLC, is pleased that Srinath (Sri) Thirumalairajan, Ph.D., Director of Process Engineering at Seagen, Inc., has joined the publication's Editorial Advisory Board.
CHANDLER, Ariz., Dec. 17, 2020 /PRNewswire-PRWeb/ -- ADC Review | Journal of Antibody-drug Conjugates, a must-read peer-reviewed journal covering all aspects of antibody-drug conjugates (ADCs), published by Sunvalley Communication, LLC, is pleased that Srinath (Sri) Thirumalairajan, Ph.D., Director of Process Engineering at Seagen, Inc., a global biotechnology company dedicated to revolutionizing cancer care, has joined the journal's Editorial Advisory Board.
As a member of the journal's editorial advisory board, Dr. Thirumalairajan will be helping to guide the publication's editorial staff to ensure it stays atop critical topics, issues, and concerns that affect the antibody-drug conjugate (development and clinical) community and the larger biotechnology industry sector.
"Our editorial advisory board is an invaluable resource for our editorial team as it provides expertise on major critical topics and helps us recognize which developments are important," said Peter Hofland, Ph.D., the journal's Executive Publisher.
"Our editorial team previously worked with Sri and we admire his expertise in the development and manufacturing of antibody-drug conjugates. With the development of novel antibody-drug conjugates, which may go beyond applications in oncology and hematology, we're looking forward to how his technical, regulatory, and business insights into the key issues our industry faces, can help us create a better publication," Hofland added.
"We really appreciate Sri's ongoing dedication and commitment as an editorial advisory board member of ADC Review | Journal of Antibody-drug Conjugates."
Sri is an experienced Chemist with 13+ years of industrial experience and is well versed in the preparation of highly potent APIs (HPAPIs), bioconjugates, analytical method development/qualification, and the establishment and implementation of safe handling procedures HPAPI.
"Serving on the editorial advisory board of ADC Review | Journal of Antibody-drug Conjugates is a great honor and I'm flattered to have been asked," Thirumalairajan said.
"I have great respect for their ongoing contributions to the antibody-drug conjugate (development and clinical) community and I hope that with my industry experience I can make a meaningful contribution to the journal and its impact in the ADC field."
Prior to joining Seagen, Sri was Executive Director – Bioconjugation Chemistry and CGMP Manufacturing at NJ Bio where he was leading the company's teams of bioconjugation, process development, and GMP manufacturing chemists. Prior to this, Sri held positions as Production Executive at Cipla Ltd. (India), as Research Scientist at Toronto Research Chemicals; as Principal Scientist at The Chemistry Research Solution LLC (TCRS); and – after TCRS' acquisition by Abzena – as Associate Director, Director, and then Senior Director of GMP Manufacturing at Abzena, where he was responsible for the process development and cGMP manufacture of ADC constructs and HPAPIs.
Sri received his Ph.D. in Chemistry from the University of Leeds (U.K.) and then joined Dalhousie University (Canada) as a Post-Doctoral/Research Fellow to perform research studies in enzymology and the total synthesis of an anti-cancer natural product. He has co-authored a significant number of publications related to synthetic/medicinal chemistry in peer-reviewed journals and is a co-inventor on two patents related to novel ADC constructs.
About ADC Review | Journal of Antibody-drug Conjugates (http://www.adcreview.com)
ADC Review | Journal of Antibody-Drug Conjugates is the premier, must-read peer-reviewed journal covering all aspects of antibody-drug conjugates (ADCs), including development and clinical application. Published online, ADC Review | Journal of Antibody-Drug Conjugates is the only journal that focuses on delivering a full spectrum of news, information as well as peer-reviewed articles focusing on ADCs.
The journal, published by Sunvalley Communication LLC, is part of the Physician's Weekly Oncology Network, a network of peer-reviewed publications and online news and educational media providing cutting-edge resources in oncology and hematology. The Physician's Weekly Oncology Network also includes Onco'Zine, The Onco'Zine Brief, Physician's Weekly Oncology Wallboards, Changing Strategies in the War on Cancer, and the International Journal of CAR T-cell Therapy (to be launched in 2021).
Editorial Advisory Board
The Editorial Advisory Board of ADC Review | Journal of Antibody-drug Conjugates includes physicians (including oncologists and hematologists), scientists, experts from the life science, biotech, pharma industry, and academia, Key Opinion Leaders (KOL), and regulators, each with a broad range of backgrounds and expertise. The Editorial Advisory Board plays a major role in maintaining the quality of the journal, and, together with the editorial team, helps set the tone and direction of the publication's editorial policy. The members of the Editorial Advisory Board also help the editorial team to determine the content of the journal (which includes identifying topics of interest and potential article ideas), review (unsolicited) manuscripts submitted for inclusion in the journal, and provide a network of potential contributors/authors.
About Sunvalley Communication (http://www.sunvalleycommunication.com)
Sunvalley Communication LLC is a global, high-science, medical communications agency that provides innovative, customized, and effective professional medical education, patient education, (online) publications development and management, educational webinars, and digital audio/podcast solutions for healthcare, biotech and pharmaceutical companies active in oncology, hematology, and cancer supportive care.
Source: Sunvalley Communication, LLC
Media Contact
Peter Hofland, Sunvalley Communication, LLC, +1 480 626 7218, [email protected]
SOURCE Sunvalley Communication, LLC
Share this article